STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink liver tumors before surgery
Disease control OngoingThis phase 2 trial tests whether combining the targeted drug regorafenib with the immunotherapy durvalumab can shrink high-risk liver cancer before surgery. The study enrolled 4 adults with stage IB to IIIA hepatocellular carcinoma. Researchers are measuring how many patients see…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo before liver surgery shows promise in early trial
Disease control OngoingThis phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC